News - Pharmaceutical, Asia-Pacific, Rare diseases

Filter

Australia to review program for life-saving drugs access

Australia to review program for life-saving drugs access

10-04-2014

The Australian government says that it will review the Life Saving Drugs Program (LSDP) - a move aimed…

Asia-PacificAustraliaFinancialHealthcarePharmaceuticalRare diseases

Promoting competition key to improving patients’ access to high cost medicines, says PHARMAC

Promoting competition key to improving patients’ access to high cost medicines, says PHARMAC

08-04-2014

New Zealand’s Pharmaceutical Management Agency, PHARMAC, has announced its intention to test out a…

Asia-PacificFinancialHealthcareNew ZealandPharmaceuticalRare diseases

Citing “unreasonable price,” New Zealand declines eculizumab funding

Citing “unreasonable price,” New Zealand declines eculizumab funding

13-12-2013

New Zealand’s Pharmaceutical Management Agency PHARMAC has declined the funding application for eculizumab…

Alexion PharmaceuticalsAsia-PacificeculizumabGlaxoSmithKlineHematologyNew ZealandPharmaceuticalPricingRare diseasesRevoladeSoliris

Daiichi Sankyo launches Biopten Granules 10% in Japan

Daiichi Sankyo launches Biopten Granules 10% in Japan

29-11-2013

Japanese drug major Daiichi Sankyo has launched natural tetrahydrobiopterin agent Biopten Granules 10%…

Asia-PacificBioptenDaiichi SankyoMarkets & MarketingPharmaceuticalRare diseases

Novo Nordisk’s NovoEight passes first stage of Japanese approval

Novo Nordisk’s NovoEight passes first stage of Japanese approval

18-11-2013

Danish insulin giant Novo Nordisk’s recombinant factor VIII product NovoEight (turoctocog alfa) has…

Asia-PacificHematologyNovo NordiskNovoEightPharmaceuticalRare diseasesRegulation

CSL Behring’s Hizentra approved in Japan for PID and SID

CSL Behring’s Hizentra approved in Japan for PID and SID

27-09-2013

The Japanese Ministry of Health, Labor and Welfare has approved Hizentra for the treatment of primary…

Asia-PacificCSL BehringHizentraImmunologicalsPharmaceuticalRare diseasesRegulation

Alexion's Soliris gets approval in Japan for rare disorder

13-09-2013

The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Soliris (eculizumab) from US drugmaker…

Alexion PharmaceuticalsAsia-PacificPharmaceuticalRare diseasesRegulationSoliris

New Zealand reaches agreement with Sanofi to fund ALS drug

11-09-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announce the approval of an agreement with…

Asia-PacificNeurologicalPharmaceuticalRare diseasesRegulationRilutekSanofi

New Zealand to widen access for type 1 and type 3 Gaucher disease drug

07-08-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of a proposal to widen…

Asia-PacificBiotechnologyCerezymeGenzymePharmaceuticalRare diseasesRegulationSanofi

New Zealand declines Alexion's funding application for Solaris

21-05-2013

New Zealand's Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to decline the…

Alexion PharmaceuticalsAsia-PacificHealthcarePharmaceuticalPricingRare diseasesSolaris

Dyax partners with CVie Therapeutics for Kalbitor in Greater China

07-02-2013

US drug developer Dyax Corp (Nasdaq: DYAX) yesterday announced a strategic partnership with CVie Therapeutics,…

Asia-PacificCVie TherapeuticsDyax CorpKalbitorLicensingPharmaceuticalRare diseases

Teijin debuts Ipsen's Somatuline in Japan; Galenica deal for Maltofer and Uro-Vaxom in China

18-01-2013

Teijin Pharma, the core company of the Japanese Teijin Group (TYO: 3401) health care business, and French…

Asia-PacificChina Medical SystemGalenicaIpsenLicensingMaltoferMarkets & MarketingPharmaceuticalRare diseasesSomatulineTeijinUro-VaxomVifor Pharma

Alnylam gets upfront $22.5 million in RNAi link with Genzyme

23-10-2012

French drug major Sanofi's (Euronext: SAN) US biotech subsidiary Genzyme has entered into an exclusive…

Alnylam PharmaceuticalsAsia-PacificBiotechnologyGenzymeLicensingPharmaceuticalRare diseasesSanofi

Japanese filings for Shionogi's metreleptin and Otsuka's tolvaptin

06-08-2012

Japanese drugmaker Shionogi (TYO: 4507) said last week that it has filed a New Drug Application with…

Asia-PacificmetreleptinNephrology and HepatologyOtsukaPharmaceuticalRare diseasesRegulationSamscaShionogitolvaptin

EMA increases interaction with Japanese regulators

30-07-2012

The European Medicines Agency has increased its level of interaction and cooperation with medicines regulatory…

Asia-PacificBiotechnologyEuropePharmaceuticalRare diseasesRegulation

Teijin and Ipsen's Somatuline cleared in Japan

01-07-2012

Japanese drugmaker Teijin Pharma (TYO: 3402) revealed last Friday that it has received manufacturing…

Asia-PacificIpsenPharmaceuticalRare diseasesRegulationSomatulineTeijin

Novartis gains NIH listing in Japan for Ilaris

23-11-2011

Swiss drug major Novartis’ (NOVN: VX) Ilaris (canakinumab), a treatment for cryopyrin-associated…

Anti-Arthritics/RheumaticsAsia-PacificIlarisNovartisPharmaceuticalPricingRare diseases

Novartis and Vectura’s NVA237 filed in Europe; positive Ph III data at ERS; Gilenya, Ilaris approved in Japan

28-09-2011

Shares of UK-based Vectura (LSE: VEC) rose 5.5% to 91 pence by midday yesterday, after the company announces…

Asia-PacificEuropeGilenyaIlarisNeurologicalNovartisPharmaceuticalRare diseasesRegulationResearchSeebriVectura

Astellas in-licenses antibody from Evec; Mitsubishi Tanabe deal with Synageva

06-09-2011

Japanese biotech firm Evec has entered a license agreement for one of its fully-human antibodies against…

Asia-PacificAstellas PharmaBiotechnologyEvecImmunologicalsLicensingMitsubishi TanabePharmaceuticalRare diseasesResearchSynageva BioPharma

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top